| ENT | ear, nose, and throat; enzootic nasal tumor; extranodular tissue |
|---|---|
| GUSTO | Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries ... |
| TPA | tannic acid, polyphosphomolybdic acid, and amino acid; 12-0-tetradecanoyl-phorbol-13-acetate; third-... |
| BCM | B-cell maturation; birth control medication; blood-clotting mechanism effects; body cell mass; body ... |
| CDC | calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division... |
| tissue distribution | Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. (12 Dec 1998) |
|---|---|
| tissue donors | Individuals suppling living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients. (12 Dec 1998) |
| elastic tissue | A form of connective tissue in which the elastic fibres predominate; it constitutes the ligamenta flava of the vertebrae and the ligamentum nuchae, especially of quadrupeds; it occurs also in the walls of the arteries and of the bronchial tree, and connects the cartilages of the larynx. Synonym: elastica, tela elastica. (05 Mar 2000) |
| tissue embedding | The technique of placing cells or tissue in a supporting medium so that thin sections can be cut using a microtome. The medium can be paraffin wax (paraffin embedding) or plastics (plastic embedding) such as epoxy resins. (12 Dec 1998) |
| tissue expanders | Inflatable reservoirs, usually made of silicone, which are implanted subcutaneously in order to generate tissue needed for surgical reconstruction. After implantation, the reservoir is inflated over several weeks by percutaneous injection of fluid. Once the tissue has grown, the expander is surgically removed and the expanded skin is used to cover the area being reconstructed. (12 Dec 1998) |
| tissue expansion | Process whereby tissue adjacent to a soft tissue defect is expanded by means of a subcutaneously implanted reservoir. The procedure is used in reconstructive surgery for injuries caused by trauma, burns, or ablative surgery. (12 Dec 1998) |
| tissue extracts | Preparations made from animal tissues or organs; they usually contain many components, any one of which may be pharmacologically or physiologically active; extracts may contain specific, but uncharacterised factors or proteins with specific actions. (12 Dec 1998) |
| tissue factor | <cell biology> Integral membrane glycoprotein of around 250 residues, that initiates blood clotting after binding factors VII or VIIa. (18 Nov 1997) |
| tissue fixation | The technique of using fixatives in the preparation of cytologic, histologic, or pathologic specimens for the purpose of maintaining the existing form and structure of all the constituent elements. (12 Dec 1998) |
| tissue fluid | The fluid in spaces between the tissue cells, constituting about 16% of the weight of the body; closely similar in composition to lymph. Synonym: tissue fluid. (05 Mar 2000) |
| tissue hormones | Hormones synthesised by cells other than those in the endocrine system. Compare: endocrine hormones. (05 Mar 2000) |
| tissue-inhibitor of metalloproteinase-1 | <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a n-glycosylated protein, molecular weight 28 kD, produced by a vast range of cell types and found in a variety of tissues and body fluids. It has been shown to suppress metastasis and inhibit tumour invasion in vitro. Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |
| tissue inhibitor-of metalloproteinase-2 | <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a 21 kD nonglycosylated protein found in tissue fluid and is secreted as a complex with progelatinase a by human fibroblast and uncomplexed from alveolar macrophages. An overexpression of timp-2 has been shown to inhibit invasive and metastatic activity of tumour cells and decrease tumour growth in vivo. Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |
| tissue inhibitor of-metalloproteinase-3 | <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a 21 kD, nonglycosylated protein. Timp-3 does not show a high degree of structural similarity unlike timp-1 and timp-2 which are structurally similar. However, it does possess a high degree of structural similarity with that of chicken timp-3 (chimp-3). Human timp-3 is of particular concern because of its potential role in cancer, arthritis, and eye diseases. Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |
| tissue inhibitor of metalloproteinases | <chemical> A family of secreted proteins (timp-1, timp-2, and timp-3) that play a crucial role in regulating the activity of the secreted metalloproteinases (collagenases, stromelysins, gelatinases). Of the three characterised, only timp-1 and timp-2 appear to have related primary structures and inhibitory properties. They influence the activation of the prometalloproteinase and act to modulate proteolysis of extracellular matrix, notably during tissue remodeling and inflammatory processes. On certain cell types, they can exhibit growth factor-like activity, and they can inhibit the tumourigenic and metastatic phenotype in cancer cells. (pharmacol ther 1993;59:329-41) Pharmacological action: antineoplastic agent, protease inhibitors. (12 Dec 1998) |